Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

@article{Barthel2011CerebralAP,
  title={Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.},
  author={Henryk Barthel and H P Gertz and Stefan Dresel and Oliver Peters and P. Bartenstein and K. Buerger and Florian Hiemeyer and Sabine M Wittemer-Rump and John Seibyl and Cornelia Reininger and Osama Sabri},
  journal={The Lancet. Neurology},
  year={2011},
  volume={10 5},
  pages={424-35}
}
BACKGROUND Imaging with amyloid-β PET can potentially aid the early and accurate diagnosis of Alzheimer's disease. Florbetaben (¹⁸F) is a promising ¹⁸F-labelled amyloid-β-targeted PET tracer in clinical development. We aimed to assess the sensitivity and specificity of florbetaben (¹⁸F) PET in discriminating between patients with probable Alzheimer's disease and elderly healthy controls. METHODS We did a multicentre, open-label, non-randomised phase 2 study in 18 centres in Australia, Germany… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 133 extracted citations

Similar Papers

Loading similar papers…